Bleeding disorders in implant dentistry: a narrative review and a treatment guide

Paul Römer1†, Diana Heimes1*,†, Andreas Pabst2, Philipp Becker2, Daniel G. E. Thiem1 and Peer W. Kämmerer1

Abstract
Purpose: Considering a high prevalence of congenital and especially acquired bleeding disorders, their heterogeneity and the multitude of possible treatments strategies, a review of the scientific data on this topic is needed to implement a treatment guide for healthcare professionals.

Methods: A selective literature review was performed via PubMed for articles describing oral surgery / dental implant procedures in patients with congenital and acquired bleeding disorders. Out of the existing literature, potential treatment algorithms were extrapolated.

Results: In order to assess the susceptibility to bleeding, risk stratification can be used for both congenital and acquired coagulation disorders. This risk stratification, together with an appropriate therapeutic pathway, allows for an adequate and individualized therapy for each patient. A central point is the close interdisciplinary cooperation with specialists. In addition to the discontinuation or replacement of existing treatment modalities, local hemostyptic measures are of primary importance. If local measures are not sufficient, systemically administered substances such as desmopressin and blood products have to be used.

Conclusions: Despite the limited evidence, a treatment guide could be developed by means of this narrative review to improve safety for patients and practitioners. Prospective randomized controlled trials are needed to allow the implementation of official evidence-based guidelines.

Keywords: Bleeding disorder, Antiplatelet drug, Anticoagulant, Hemophilia, Factor deficiency, von Willebrand disease

Background
Every dental surgical intervention involves a certain risk of postoperative bleeding. In dental implantology, the treatment may involve moderately to highly invasive surgical procedures. From “simple” tooth extractions with immediate implant placement to complex multi-stage procedures involving augmentations and/or sinus lift procedures, the patient-specific bleeding risk must always be correctly assessed, and sufficient precautions have to be implemented. The incidence of postoperative bleeding after dental surgical procedures in healthy individuals is approximately 0.2–3.3%, whereas in patients with coagulation disorders, such complications have been reported to be significantly more common at 8.6–32.1% [1]. Special attention and preparation is therefore required for those patients who are exposed to an increased risk of bleeding.

The diseases in question can be divided into congenital and acquired blood coagulation disorders. Congenital coagulation disorders include the von Willebrand–Jürgens syndrome, which affects up to one percent of the population, and hemophilia A and B, subtypes of which are mild, moderate, and severe, depending on the residual factor activity [2, 3]. Acquired blood coagulation disorders are often concomitant symptoms of liver, kidney, and bone marrow diseases, which, depending on their severity and genesis, require particular caution, especially when invasive surgical procedures are imminent.
Furthermore, in addition to congenital and acquired blood coagulation disorders, knowledge of drugs that influence blood coagulation is becoming increasingly important. Approximately, one percent of the German population is already being treated with oral anticoagulants [4]. It is important to know the patient’s general diseases and to be able to distinguish between different forms of oral anticoagulation drugs and their half-life period. The purpose of this narrative review is to provide an overview of the current literature and, based on these results, to present recommendations for the treatment of patients with those very bleeding disorders.

Materials and methods
A selective literature review was performed via PubMed for articles describing oral surgery/dental implant procedures in patients with congenital and acquired bleeding disorders. Out of the existing literature, potential treatment algorithms were extrapolated. Randomized controlled trials (RCTs), prospective studies, observational studies, reviews, and retrospective studies were preferred; case reports were used where no further data sources were available due to the scarcity of data.

Literature review on bleeding disorders in dentistry

Congenital bleeding disorders
Congenital bleeding disorders are hereditary diseases which are clinically characterized by an increased tendency to bleeding (spontaneous and/or after trauma/invasive procedures) due to genetic abnormalities concerning quantitative and/or qualitative components of the coagulation system.

Extent and severity of bleeding events depend on such factors as severity of the corresponding pathology, local and systemic patient factors and type of intervention. If the treatment is not sufficiently adapted to the patient’s needs, extended hospitalization time or psychological traumatata may occur. A review of dental interventions on patients with mild blood clotting disorders also showed that unnecessary over-treatment was performed in 59% of the cases [5].

von Willebrand syndrome
Up to one percent of the population suffers from von Willebrand disease (VWD), a usually autosomal dominant inherited quantitative or functional deficit of the factor VIII carrier protein, affecting the von Willebrand factor (VWF). However, the prevalence of clinically relevant VWD is significantly lower.

VWD results from an either quantitative (type 1 or 3) or qualitative (type 2) deficiency of VWF in the patients’ blood plasma (Table 1). Affected patients can suffer from varying degrees of bleeding during and after invasive procedures. Blomback et al. reported of a high complication rate in patients with unknown VWD at the time of surgical intervention (67%), while corresponding complications only occurred in 6.7% of patients who were aware to have the disease and therefore had been treated systematically [6].

Desmopressin (usually 0.3 µg/kg bodyweight [BW] at least 1 h before intervention [7]) is used systemically in patients with type-1-vWD and available residual concentration of factor VIII and VWF-concentrations of > 10 IE/dl. Patients who are not responding to desmopressin, as well as patients with other types of vWD can be treated with VWF-containing factor VIII concentrates [8–10]. De Padua et al. investigated whether patient-specific therapy protocols, based on type and severity of the vWD and the invasiveness of the intervention, could prevent perioperative bleeding. Local hemostatic measures (gelatin cone, fibrin glue, adapting sutures, compression, application of tranexamic acid, cooling) were applied in all procedures. Overall, no peri- or post-operative bleeding events could be observed [10].

In case of type 1, the majority of affected patients only shows slightly decreased VWF-plasma concentrations and typically no hemorrhagic diathesis. Anyhow,

Table 1 Different types of von Willebrand disease (VWD)

| Type 1 | Quantitative deficiency of VWF | 80% of patients |
|-------|-------------------------------|----------------|
| Type 2 | A: Qualitative deficiency of VWF with reduced binding ability of VWF to platelets and collagen and reduced high molecular monomers | 15–20% of patients |
|       | B: Qualitative deficiency of VWF with increased affinity for platelet-derived GPIb-receptor and reduced high molecular monomers |               |
|       | M: Reduced affinity to platelets with a functional defect in primary hemostasis and decreased ratio of ristocetin cofactor activity to VWF antigen |               |
|       | N: Reduced affinity for factor VIII |               |
| Type 3 | Complete absence or severe reduction of VWF | 0.5–1.5% of patients |

The VWD is divided into three types (with four subtypes of type 2). In type 1 and 3, von Willebrand factor (VWF) is quantitatively decreased. In type 2 (A,B,M,N) the VWF is qualitatively defective.
it could be shown that in this cohort, despite minor vWF-plasma reduction, there is a correlation to a clinically increased bleeding phenotype. Potential reasons for this can be a reduction in vWF synthesis and/or in its consecutive secretion, overall, however, there is not yet enough evidence here [11, 12]. Doherty et al. examined a total of 60 patients with slightly decreased vWF-plasma levels in combination with a known history of bleeding phenotype, in which at least one elective procedure had been performed before “low vWF bleeding phenotype” was diagnosed. Retrospectively, in 62.5% of the cases (30/48) bleeding events could be observed and further measures, such as compression, sutures or transfusions became necessary in 43.8% of the cases (23/48). As part of a prospective study, 40 dental procedures (mostly single tooth extractions) were performed under local hemostatic measures in addition to systemic administration of tranexamic acid (1 g/3 × days) in 25% of the cases and desmopressin (0.3 μg/kg BW) in 72.5% of the cases. As a result, only 10% of the treated patients showed post-interventional bleeding events [13].

Conclusion The peri- and post-interventional care of patients with vWD for dental implantology requires close interdisciplinary collaboration, especially with hematologic disciplines. Desmopressin and factor concentrates are used depending on the type of vWD to significantly reduce the risk of bleeding events. The elective management of patients with slightly decreased vWF and “bleeding phenotype” is a major clinical challenge with a current lack of evidence and uncertain definition. Intravenous administration of desmopressin is a safe and effective treatment for elective dental procedures in those patients. However, especially in elderly patients with comorbidities, contraindications to administration of desmopressin are frequent.

Hemophilia A and B
Deficiencies of clotting factor VIII (hemophilia A) and factor IX (hemophilia B) occur with a prevalence of approximately 1:10–20,000 and 1:30–60,000, respectively [2, 3], of which about 2/3 of the affected hemophilia patients indicate a positive family disposition, while other clinical pathologies are more likely to be spontaneous new mutations. Hemophilia A and B are divided into three degrees of severity, depending on the quantitative deficit of remaining factor activity [14]. Residual factor activities of >25% are required for a generally normal hemostasis while most of the patients feature levels below 5% [15]:

mild hemophilia: factor activity 5–40%,
moderate hemophilia: factor activity 1–5% and severe hemophilia: factor activity <1% [16, 17].

Infusion of factor preparations is considered the gold standard to counteract bleeding events, however, frequent and weight-adapted doses are required due to short half-life periods [17]. The main complication of substitution therapy with a life-long risk of 5–40% is the occurrence of antibodies against factor VII or IX in the recipient’s blood, which are known as “inhibitors” that neutralize the effect of the factor concentrate and thus making the treatment more difficult. Therefore, patients with mild hemophilia are usually only treated with concentrate of the analogous factor in the case of a surgical intervention, an accident, or a serious injury [18].

Hence there is a need to carefully consider the use of factor substitution, which is why, for example, in procedures such as regular dental examination, supragingival scaling, root canal treatments, simple fissure sealing and restorative dental treatments without the need for conduction a nerve block, no extended measures need to be prepared. In contrast, tooth extraction, implant insertion, or treatment of advanced periodontal diseases tend to require substitution of the missing factors and/or additional local hemostatic measures (Figs. 1, 2, 3, 4) [14, 19, 20]. Patients who nonetheless have developed inhibitory antibodies are subsequently primarily treated with either recombinant activated factor VII or activated prothrombin complex concentrates derived from blood plasma [21].

As an alternative to factor concentrates, desmopressin can be used in mild cases. However, the evidence for the exact protocols is limited and there is little or no consensus regarding the ideal level and duration of appropriate therapies for preventing bleeding in oral surgery. The use of local hemostyptics alone does not seem to be sufficient, especially in cases of moderate or severe hemophilia [14], making additional peri-interventional adjuvants necessary during treatment.

In a review article, Bajkin und Dougall examined hematological preparation protocols (factor concentrates pre- and/or post-operatively, Desmopressin, systemic antifibrinolytic drugs 5–10 days) and calculated a rebleeding rate of 3.9–27.8%. No evidence could be found whether hemophilia patients should be treated as an outpatient or inpatient, although severe bleeding complications were only reported in few cases [22, 23]. Laino et al. attempted to extract guidelines for the treatment of hemophilia patients in the context of oral and maxillofacial surgery form existing literature (7 articles) [24]. The authors point out that ingestion of non-steroidal anti-inflammatory drugs (NSAIDs) is considered to be contraindicated due to their negative effect on platelet aggregation, while paracetamol and codeine are more recommended [24], although no corresponding studies in dental or oral surgery are available. Patients with
Fig. 1 Exemplary treatment scheme for noninvasive dental treatments. No risk (blue) and low risk (green) (acc. to [2]). TXA: tranexamic acid.

Fig. 2 Exemplary treatment scheme for slightly invasive dental treatments. Low risk (green) and moderate risk (yellow) (acc. to [2]). TXA: tranexamic acid, DDAVP desmopressin.

Fig. 3 Exemplary treatment scheme for moderate-risk dental treatments. Moderate risk (yellow) (acc. to [2]). TXA: tranexamic acid, DDAVP: Desmopressin.
mild-to-moderate hemophilia benefit from less invasive forms of local anesthesia, such as infiltration anesthesia or need for factor substitution before more invasive forms, but evidence is limited [24].

**Conclusion** Overall, only poor-to-moderate evidence exists for oral surgical treatment of hemophilia patients. The relevant guidelines are based primarily on empirical data obtained from clinical experience of centers specialized in the treatment of hemophilia. A recent review [22] reported similar postoperative bleeding rates in patients with hemophilia after dental extractions who had received factor concentrates either both preoperatively and postoperatively or only before intervention.

**Congenital bleeding disorders and local anesthesia**

Dougall et al. conducted a prospective study (71 patients, no control group) with patients deficient in factors VIII, IV and XI (mild to severe hemophilia) who required dental procedures under local anesthesia [25]. In these patients, buccal infiltrations were performed without further hematological treatment. The authors observed no bleeding or hematoma at the injection site concluded that local anesthetics can be administered safely via buccal injection in patients with mild, moderate and severe hemophilia without additional factor coverage [25]. This is analogous to the World Federation of Hemophilia guidelines, which describe infiltration anesthesia in people with hemophilia as safe and without the need for factor substitution [19]. In contrast, factor substitution is recommended before block anesthesia because of the increased potential for hemorrhage with the risk of intramuscular hematoma and thus, at worst, potential airway obstruction. Nonetheless, it must be noted that this guideline was consensus-based due to the lack of supporting clinical data and the absence of reports of life-threatening bleeding events after such block anesthesia. For example, Hewson et al. reported 41 block anesthesias in patients with congenital coagulation disorders without evidence for complication [26].

**Congenital bleeding disorders and topical hemostyptics**

In the dental and oral surgical treatment of patients with congenital coagulation disorders, the recommendations for bleeding prophylaxis are based on the four pillars:

1. Compensation of factor deficiency by appropriate concentrates
2. Desmopressin administration in a suitable collective
3. Systemic administration of antifibrinolytics
4. Use of topical antifibrinolytics and topical hemostyptics.

The choice for a locally effective topical hemostyptic can potentially limit the need for systemic substitutions which may be relevant for clinical as well as economic and social reasons [26]. The establishment of a stable blood clot usually provides adequate hemostasis as a “natural dressing”.

The management of peri-interventional bleeding in patients with vWD using local measures such as antifibrinolytics was systemically investigated by van Galen et al., but no corresponding randomized trials could be identified, thus no higher-grade evidence is available here [27]. A recent Cochrane-Review failed to demonstrate any efficacy for oral surgery in hemophilia patients due to a limited number of appropriate studies [28], although a beneficial effect of these drugs in preventing postoperative bleeding could be proven [27].
A treatment tool for congenital bleeding disorders

Using the Dental Bleeding Risk Assessment and Treatment Tool (DeBRATT), Rasaratnam et al. stratified patients according to the invasiveness of the dental procedure (noninvasive, mild, moderate, and highly invasive) and the severity of the coagulopathy (mild, moderate, severe). The bleeding risk groups were divided into four groups:

1. No risk (blue)
2. Low risk (green)
3. Moderate risk (yellow)
4. High risk (red).

Rasaratnam et al.'s analysis of 200 dental procedures performed in 30 patients with congenital coagulation disorders following this protocol only reported one case (0.5%) of postoperative bleeding. Yet, because this was a retrospective evaluation, there may have been a bias towards undocumented bleeding complications [5].

Acquired bleeding disorders

There are several acquired diseases that can directly affect the normal hemostasis. These include, for example, pathologies of the liver, kidneys, bone marrow and/or immune system.

Liver diseases

It is known that patients with (severe) liver diseases have altered blood coagulation of a multifactorial etiology. Most coagulation factors as well as thrombopoietin are formed in the liver. The progression of liver diseases is associated with a decrease in platelet adhesion to the endothelium along with lower platelet aggregation and poorer platelet activation [29]. Portal hypertension also leads to hypertrophy of the spleen and an inverse relationship between spleen size and platelet count via sequestration of platelets within the spleen. Thus, thrombocytopenia represents the most common hematologic complication in the presence of chronic liver diseases [30, 31].

Furthermore, quite a few of the affected patients exhibit chronic anemia, depletion of vitamin K due to malnutrition, decreased intestinal absorption or impaired hepatic storage function, increased fibrinolytic activity, and even, especially in the case of ethyl- toxic liver injury, additional bone marrow suppression [32]. Both prothrombin time (PT) and activated partial thromboplastin time (aPTT) are prolonged in chronic liver disease and severe bleeding can occur after dental implantation [33]. For this reason, it is recommended that liver function and coagulation tests are performed in affected patients prior to invasive oral procedures.

Patients at risk of vitamin K malabsorption may require oral or intravenous vitamin K substitution before the procedure, and patients with advanced liver damage may require additional pre-interventional plasma or platelet infusion [34]. Despite advances in collection, storage and transfusion of platelet concentrate, there are risks such as infections, alloimmunization, as well as febrile and non-hemolytic reactions [35]. Local hemostyptic measures should always be applied because prophylactic transfusions alone do not result in adequate hemostasis despite apparently "normal" values [36]. Overall, it is important to contact the patient's primary care physician/hematologist regarding patient preparation to quantify the expected interventional risk [37–39].

Some authors were able to identify a significant association between liver cirrhosis and periodontitis [40–42]. In final liver disease and before transplantation, rehabilitation of dental foci is the therapeutic gold standard [43]. Accordingly, Concoro et al. performed 1329 tooth extractions in 346 patients before liver transplantation [44]. Patients with platelet count of <50,000/μL (this threshold is generally used although it is based on expert opinion and may expose patients to unnecessary transfusions [45]) received a platelet concentrate, and in patients with an International Normalized Ratio (INR) >2.5, procedures were postponed until lower values could be achieved. Local hemostyptic measures were performed (curettage, digital pressure, insertion of gelatin sponges, adaptive suturing, compresses soaked in tranexamic acid). Bleeding events were recorded in 1.4% of the cases [44]. Accordingly, Pereira et al. reported rebleeding in 1.7% of tooth extractions in liver transplant candidates [32]; in other studies, the rebleeding rate was 0–2.9% [34, 36, 46]. In contrast to Cocero et al., Medina et al. concluded that patients with liver cirrhosis do not require transfusion products above a platelet count of 16,000/μL and an INR <3 and that the use of local hemostatic measures is sufficient in these cases [47]. The comparison of preoperative intranasal desmopressin administration with preoperative plasma transfusion in individuals with a platelet count of 30–50,000/μL and INR of 2–3—both in combination with local hemostatic measures—showed no differences regarding postoperative bleeding events [48]. In contrast, extractions in patients with undiagnosed liver disease and without appropriate precautions may quite well result in life-threatening bleeding [49, 50].

Conclusion In patients with liver disease prior to dental surgical procedures, preoperative preparation is essential and prophylactic transfusion measures alone do not ensure adequate hemostasis. Patients with severe liver disease could safely undergo oral surgical procedures.
Renal diseases
Renal diseases result in impaired hematopoiesis for several reasons: Among other factors, platelet production is restricted due to compromised thrombopoietin secretion [51]; intrinsic platelet defects occur, as healthy renal glomular endothelial cells express vWF; abnormal platelet adhesion is present in renal injury and general vasodilation occurs due to increasing prostaglandin levels [37]. Erythropoietin is also impaired, potentially leading to anemia. This anemia increases the uremic tendency of qualitative thrombocyte dysfunction. In uremic patients, this disorder can be controlled, for example, by administration of Desmopressin, conjugated estrogen, erythropoietin, dialysis or by infusions of platelet concentrates [52].

In case of advanced kidney disease, dialysis is the therapy of choice. Hemodialysis requires the use of an anticoagulant in the form of heparin to maintain access patency and facilitate filtration of toxic blood compounds. This heparinization associated with mechanical trauma to platelets may decrease platelet counts and increase hemorrhagic risk. This tendency is exacerbated by preexisting capillary fragility and anemia. Particularly, special attention should be paid to the effect of heparin in patients with chronic renal failure undergoing hemodialysis, before and during oral surgical treatment [53]. Communication between the dentist and nephrologist is highly recommended in these cases. Dental treatment with the risk of bleeding should be postponed to the day without dialysis [54]. In an emergency, Protamine can be administered as an antagonist to heparin. For patients receiving oral anticoagulation with vitamin K antagonists, the INR should be determined before intervention, although minor surgical procedures can be safely performed with an INR<4 [55, 56]. Pendem et al. performed tooth extractions in 36 patients with severe renal disease using antihypertensive and hemostatic measures (local anesthesia without epinephrine, socket curettage, gelatin sponges, oxidized cellulose, and sutures) without postoperative bleeding events [57]. Overall, local hemostytic measures should always be used [38, 54]. Greenwood et al. additionally recommend the (intranasal) administration of Desmopressin to prevent postoperative bleeding [37]. Because of renal excretion of numerous pharmaceuticals, renal dysfunction may lead to an increased bleeding tendency associated with oral anticoagulants/antiplatelet agents [58].

Conclusion When treating patients suffering from kidney disease, prior to dental surgical procedures, it is important to closely coordinate the planned procedure with the nephrologist in charge to consider a possible deterioration of the patient’s general condition during and after the dental treatment.

Hemostasis protocols are based on the severity of the disease and the planned procedure. In addition to bleeding tendencies, special attention should be paid to drug interactions.

Bone marrow diseases
The bone marrow produces hematopoietic stem cells and normally only mature cells are released from the bone into the systemic circulation. Any disorder that causes an abnormality in the production of immature progenitor or mature cells may alter the bleeding tendency of affected patients. Normal bone marrow function can also be disrupted by infections such as tuberculosis or malignancies like leukemia [38].

Leukemia is a heterogeneous group of hematologic disorders characterized by increased and uncontrolled production of nonfunctional leukocytes. By spreading in the bone marrow, they displace the usual hematopoiesis, resulting in anemia, thrombocytopenia and leukopenia. In the case of acute myeloid leukemia, Mester et al. only recommended invasive dental procedures in the presence of a platelet count of >50,000/μL and a neutrophil count of >100/μL [59]. In a retrospective cohort study including 68 patients with a total of 200 dental extractions, an increased bleeding tendency was reported when platelet counts were 20,000/μL [60]. Another guideline states that although prophylactic platelet concentration is not required before dental extractions, transfusions with the goal of a platelet count of >10,000 may be useful [61]. In summary, in the case of thrombocytopenia, thrombocyte transfusions may be necessary before invasive dental procedures [38]. If the patient is already receiving systemic therapy, invasive dental procedures are appropriate during periods of remission or between chemotherapy cycles while cell and platelet counts are at their optimum. Accordingly, Akashi et al. did not detect any rebleeding events when platelet counts were >50,000/μL and topical hemostytics were used [62].

Conclusion Consultation of the treating general physician/hematologist and the application of local hemostytic measures including the use of Desmopressin and tranexamic acid is of paramount importance.

Oral anticoagulants and antiplatelet therapy
Approximately one percent of the German population is treated with oral anticoagulants. When a patient treated with oral anticoagulants must undergo an elective procedure or a comparatively minor operation such as implant placement, the risk of bleeding must be weighed against the risk of thrombosis associated with interruption of
Anticoagulant medication [4, 63]. According to Nizarali et al., dental procedures that are unlikely to cause bleeding include routine conservative, restorative, and orthograde endodontic procedures with buccal, intraligamentary, and intrapapillary local anesthesia, supragingival scaling, prosthodontic procedures, and adjustment of orthodontic appliances. In these cases, implementation without measuring INR, discontinuing heparin therapy, or changing the anticoagulant medication is recommended. However, the scenario is different for other surgical procedures and types of local anesthesia with a higher bleeding risk [38, 53]. Recommendations for oral surgery in patients treated with oral anticoagulants and antiplatelet therapy are displayed in Figs. 5, 6, 7.

**Anticoagulation with vitamin K antagonists**

Vitamin K antagonists inhibit the carboxylation of the vitamin K dependent coagulation factors II, VII, IX and X, as well as proteins C and S. Therapeutic levels of vitamin K antagonists are monitored by measuring the INR, which should be kept within a narrow therapeutic range to prevent thromboembolic events without causing bleeding complications. After determination of the individual risk pattern, patients can be assigned to either a low-intensity (2.0–3.0) or high-intensity (2.5–3.5) INR therapy range [64].

**Anticoagulation with direct oral anticoagulants**

Direct Oral Anticoagulants (DOACs) were developed as an alternative to vitamin K antagonists. Their main advantages include an immediate onset of action, fewer drug and food interactions, a short half-life, and fixed-dose anticoagulation without the need for regular monitoring. DOACs act by directly inhibiting activated clotting factors. Currently available DOAC include Dabigatran (inhibiting factor IIA) and rivaroxaban, edoxaban and apixaban (each inhibiting factor Xa) [65]. Based on cumulative evidence from large randomized multicenter trials, DOACs have been shown to be noninferior to vitamin K antagonists in preventing thromboembolic events, although the risk of serious bleeding events may be lower in patients with atrial fibrillation [66, 67]. In older studies, the death rate of patients treated with DOACs who experienced severe bleeding was similar to or even lower compared to patients treated with vitamin K antagonists, despite the lack of availability of antidotes [68]. Two antidotes were approved: idarucizumab to dabigatran and andexanet alfa to rivaroxaban / apixaban reversal [69, 70]. However, in addition to the high cost of antidotes, it should be noted that the incidence of thromboembolic events increased dramatically to as high as 18% after administration of the approved antidotes [71].

**Fig. 5** Clinical recommendations for oral surgery in patients treated with vitamin K antagonists
Antiplatelet therapy

Antiplatelet agents are prescribed for primary and secondary prevention of cardiovascular disease, treatment of acute myocardial and cerebral ischemia, and long-term treatment of (transient) ischemic stroke. They are used alone or in combination with other antiplatelet
agents or anticoagulants and inhibit platelet aggregation and thrombus formation. Acetylsalicylic acid exerts its anticoagulant effect even at low doses via irreversible inhibition of cyclooxygenase-1 (COX-1), thus preventing thromboxane A₂ formation and having an effective duration analogous to platelet survival (8–11 days). Clopidogrel, ticlopidine, prasugrel and ticagrelor inhibit the adenosine phosphate (ADP)-induced expression of GP IIb/IIIa via inhibition of the P2Y2 receptor, which is required for platelets to attach to fibrinogen and other platelets.

A treatment tool for patients with anticoagulant or antiplatelet therapy
The patient and the physician have four options before invasive procedures:

1. Discontinuation of medical therapy before and after the procedure
2. Continuation of the therapy
3. Reduction of anticoagulant/antiaggregational therapy
4. Temporary discontinuation of oral anticoagulant therapy while providing a comparatively short-acting anticoagulant (e.g., unfractionated or low-molecular-weight heparin) to bridge the perioperative period.

Oral anticoagulants—thromboembolism risk by discontinuing the medication
The risk of thromboembolism when discontinuing vitamin K antagonists has been poorly studied. This represents a critical gap in current knowledge because the bleeding risk associated with “bridging” by heparin is also justified by the fact that such bridging therapy prevents potentially lethal thromboembolic events that would otherwise occur. Without sufficient knowledge concerning the individual risk of potential thromboembolism events, an appropriate risk–benefit evaluation cannot be adequately performed, however, some publications repeatedly cited refer on unclear and/or poorly described events [72, 73].

In a first prospective multicenter cohort study, García et al. reported of 1024 patients anticoagulated with Warfarin in whom the anticoagulant had been bridged with low-molecular-weight heparin in 8.4% of the cases and discontinued in the remainder of cases. In 83.8% of the cases, the duration of anticoagulant-discontinuation was ≤5 days. During the 30-day follow-up period, seven patients in whom the anticoagulant had been discontinued and not bridged developed thromboembolic events. Four of the patients with thromboembolic events had primarily received Warfarin because of atrial fibrillation. Furthermore, in this group, 9 secondary bleeding events (0.8%) occurred. In the group with bridging 14 events of secondary bleeding (13%) emerged. Overall, the study showed that thromboembolic events are rare but do occur in low- to intermediate risk outpatients undergoing short-term minor intervention if Warfarin therapy is interrupted. On the other hand, analogous to the literature, “bridging” with Heparin was found to increase the risk of bleeding significantly [74–76]. Despite the large number of patients and cases in the study by García et al., the small number of thromboembolic events [which, is similar to rates with interrupted administration as well as continued administration of DOACs and vitamin K antagonists (0.16–1.9%) [77–81] limits the ability to draw definitive conclusions about the overall risk of interrupting perioperative therapy with a vitamin K antagonist for each individual patient. The risk of peri-interventional thromboembolism is certainly influenced by several patient-, procedure-, and drug-specific factors that collectively influence thrombogenicity. Furthermore, Warfarin has a significantly shorter half-life period than phenprocoumon, which is commonly used in Germany and thus cannot be directly compared.

Oral anticoagulants—bridging or no bridging?
Low-molecular-weight heparin is often recommended as part of so-called “bridging” during temporary interruption of oral anticoagulants, although its safety and efficacy has not been proven for all procedures and for all patient-specific risk groups. In 2012, Siegal et al. concluded in their systematic literature review that patients who received “bridging”, compared with a group in which oral vitamin K antagonist therapy was continued, had a higher bleeding risk and a similar rate of thromboembolic events [79, 82]. In the following years, an increasing number of studies demonstrated the practical advantages of continued therapy with oral anticoagulants over perioperative bridging [83]. In 2015, Douketis et al. addressed the question of whether peri-interventional bridging with low-molecular-weight heparin is necessary in patients with atrial fibrillation and existing oral anticoagulation with Warfarin. For this purpose, they conducted a randomized, double-blinded, placebo-controlled clinical trial comparing 891 bridged patients with 915 patients receiving a placebo regarding bleeding and thromboembolic events in minor (89%) and major surgical procedures at a follow-up duration of 30 days. In total, there was no apparent difference in terms of thromboembolic events between the groups. Bleeding events occurred significantly more frequently in the bridging group [80]. In 2017, Young et al. published a systematic review comparing the risk of major bleeding and thromboembolic events in patients bridged with heparin versus patients with continued oral anticoagulation (vitamin K/DOAK).
Here, bridging led significantly more often to bleeding events (odds ratio [OR]: relevant bleeding 3.23; OR minor bleeding 1.52). Between the two groups, no differences in thromboembolic events were observed [84].

DOACs, with their short half-life period (5–15 h in patients with normal renal function), were shown to have a low incidence of thromboembolic events (0.2–0.6%) without bridging, whereas bridging with heparin resulted in an increase in bleeding complications without additional thromboembolic benefit. Thus, continuation or short-term interruption of DOAC therapy without bridging has been recommended for most invasive procedures with low to moderate bleeding risk [80, 85].

Oral anticoagulants—discontinue or continue?
In a systematic review by Kämmerer et al., it was concluded that dental surgical procedures such as implant insertion in patients under oral anticoagulation with vitamin K antagonists can be safely performed without changing the anticoagulant regimen if the anticoagulation is in the therapeutic range (INR < 4) and local hemostatic measures are implemented [86]. Other studies reported similar results [87, 88]—incorporating a study with DOAC [89]. Hiroshi et al. conducted a multicenter, observational cross-sectional study, examining data from 496 patients in which vitamin K antagonization with Warfarin had been continued for tooth extraction (INR ≤ 3, 7 days before intervention) and compared them with 2321 patients treated while vitamin K antagonist therapy was discontinued. Bleeding events were significantly more frequent in the group receiving ongoing anticoagulant therapy, whereby age < 65 years, higher pretherapeutic INR, additional use of antiplatelet agents, and the presence of current inflammation at the extraction site positively correlated with those very bleeding events [90]. In contrast, a meta-analysis by Yang et al. was able to calculate a non-significantly different incidence of postoperative bleeding complications of 10.8% with continued oral anticoagulation versus 8.3% with discontinuation of anticoagulation for tooth extraction. In every included study, no severe bleeding occurred while using local hemostatic measures and sufficient hemostasis could be achieved in all cases by application of local measures [91].

Hanken et al. compared 52 dental surgical procedures (osteotomy, implantation) under Rivaroxaban (20 mg/day) with 285 procedures without anticoagulation in a retrospective observational study. The authors found a significantly higher bleeding rate (11.5% versus 0.7%) in the DOAC patient group [92]. In contrast, no difference could be observed in other studies [44, 93, 94]. Galletti et al. placed 57 implants in 12 patients receiving Rivaroxaban (discontinued 24 h before the procedure) without postoperative bleeding events [65]. In a recent literature research including six studies, Manfredi et al. were also unable to identify any differences in bleeding and thromboembolism in patients undergoing invasive dental procedures, while DOAC was either continued or (briefly) discontinued [90].

Mauprivez et al. compared 31 patients on continued DOAC medication with 20 patients on continued vitamin K antagonization (INR 2–3) for tooth extraction while using obligatory hemostatic measures and found no differences in terms of bleeding events. Notably, all bleeding events in the factor Xa inhibitor group occurred in patients in whom the intervention took place < 4 h after the last dose of DOAC [95].

Therefore, in the case of urgent interventions requiring surgery within hours, delaying surgery by at least 4 h (pharmacologically reasonable 12–24 h) after last DOAC administration should be considered, because a substantial amount of the drug is eliminated within this period of time [70, 96]. Overall, as discussed above, bridging is currently not recommended with DOAC, although either short discontinuation or continuation of DOAC appears to be appropriate for interventions with low bleeding risk such as dental surgical procedures. If DOAC is discontinued, it should be reinitiated post-interventional as

| Creatinine-clearance | Dabigatran Surgical bleeding risk | Rivaroxaban, apixaban, edoxaban Surgical bleeding risk | Duration of DOAC interruption before surgery |
|----------------------|----------------------------------|------------------------------------------------------|---------------------------------------------|
|                      | Low                              | High                                                 | Recommended time of DOAC interruption before surgery |
| ≥ 80 ml/min          | ≥ 24 h                           | ≥ 24 h                                               | ≥ 24 h                                      |
| 50–79 ml/min         | ≥ 36 h                           | ≥ 72 h                                               | ≥ 36 h                                      |
| 30–49 ml/min         | ≥ 48 h                           | ≥ 96 h                                               | ≥ 48 h                                      |
| < 30 ml/min          | No sufficient evidence           | No sufficient evidence                               | ≥ 36 h                                      |

Table 2 Perioperative management of patients taking DOAK during elective interventions (based on [101])

| Creatinine-clearance | Dabigatran Surgical bleeding risk | Rivaroxaban, apixaban, edoxaban Surgical bleeding risk | Duration of DOAC interruption before surgery |
|----------------------|----------------------------------|------------------------------------------------------|---------------------------------------------|
|                      | Low                              | High                                                 | Recommended time of DOAC interruption before surgery |
| ≥ 80 ml/min          | ≥ 24 h                           | ≥ 24 h                                               | ≥ 24 h                                      |
| 50–79 ml/min         | ≥ 36 h                           | ≥ 72 h                                               | ≥ 36 h                                      |
| 30–49 ml/min         | ≥ 48 h                           | ≥ 96 h                                               | ≥ 48 h                                      |
| < 30 ml/min          | No sufficient evidence           | No sufficient evidence                               | ≥ 36 h                                      |
sooner as possible [97]. Kim et al. subsumed the current evidence (Table 2), with dental surgical procedures most likely to be classified in the minimal to lower bleeding risk group [82].

**Antithrombotic therapy—discontinue or continue?**

Analogous to oral anticoagulation, there are no reports of uncontrollable or even lethal bleeding events under antiplatelet therapy during invasive dental procedures. For dentoalveolar surgery, several smaller prospective observational studies investigated potential bleeding complications while continuing acetylsalicylic acid. They concluded no significant differences in intraoperative blood loss, bleeding duration, or bleeding complications when local hemostatic measures were used [98–100]. A meta-analysis including 14,981 patients in whom perioperative continuation was compared with discontinuation of low-dose acetylsalicylic acid found that 0.6% of patients with discontinued acetylsalicylic acid therapy suffered vascular events [101]. In addition, a meta-analysis of 50,279 patients showed that discontinuation of acetylsalicylic acid had adverse effects. It was correlated with a threefold increased risk of serious cardiac events, with an even increased risk (OR 89.78) for patients with intracoronary stents [102].

Monotherapy with Clopidogrel should be continued for dental surgical procedures [103], but—according to expert consensus—can also be discontinued seven days before surgery in patients at low risk of thromboembolism and continued after surgery once hemostasis is achieved [104, 105].

Discontinuation of dual therapy with acetylsalicylic acid and Clopidogrel is associated with a 5- to 10-fold increased risk of myocardial infarction in patients with coronary stents. Here, the risk appears to be inversely proportional to the date of prior cardiac intervention [106]. In contrast, in studies analyzing patients receiving dual antiplatelet aggregation only minor bleeding could be reported in the setting of dental surgical procedures that could be stopped by using local hemostatic measures [107, 108].

**Hemostatic measures in patients with anticoagulant or antiplatelet therapy**

For most patients receiving oral anticoagulants and/or antiplatelet agents, local compression is sufficient to achieve hemostasis [109, 110], although, in particular, an increased INR, difficulty in achieving hemostasis intraoperatively, and higher serum creatinine concentrations may be additional risk factors for postoperative bleeding [111]. If further measures are necessary, the use of sutures, collagen, oxidized cellulose, absorbable sponges, chitosan, bone wax, and fibrin glue, for example, have been proven to be effective [112–114] and can be used to achieve successful hemostasis even with INR values outside the therapeutic range [115]. However, evidence as to which hemostatic regimen should be preferred cannot be extracted from the literature [86, 109, 112].

In a systematic Cochrane literature review, Engelen et al. evaluated the efficacy of antifibrinolytics in preventing bleeding complications in patients receiving oral anticoagulation (vitamin K antagonists or DOACs) undergoing dental surgery. Overall, a positive effect of locally applied tranexamic acid (mostly 5% concentration, 3–4 × /days) to prevent oral bleeding events could be demonstrated [116].

**Conclusion**

Despite the limited evidence, a treatment guide could be developed by means of this narrative review to improve safety for patients and practitioners. The major shortcoming of this study is the lack of a systematic approach to this review. Prospective randomized controlled trials are needed to allow the implementation of official evidence-based guidelines.

**Abbreviations**

RCT: Randomized controlled trial; VWD: Von Willebrand disease; VWF: Von Willebrand factor; NSAID: Non-steroidal anti-inflammatory drugs; DeBRATT: Dental Bleeding Risk Assessment and Treatment Tool; PT: Prothrombin time; aPTT: Activated partial thromboplastin time; INR: International normalized ratio; DOAC: Direct oral anticoagulant; COX-1: Cyclooxygenase-1; ADP: Adenosine phosphate; OR: Odds ratio.

**Acknowledgements**

None.

**Author contributions**

Conceptualization, PWK; methodology, PWK; validation, PWK; DH, AP, DT; formal analysis, PR, DH, AP, PT, PWK; investigation, PR, DH, AP, PB, DT, PWK; data curation, PWK; writing—original draft preparation, PR, DH, PWK; writing—review and editing, PR, DH, AP, PB, DT, PWK; visualization, PR, DH, PWK; supervision, PWK; project administration, PWK. All authors have read and agreed to the published version of the manuscript. All authors read and approved the final manuscript.

**Funding**

Open Access funding enabled and organized by Projekt DEAL.

**Data availability**

The data that support the findings of this study are available in the National Center for Biotechnology Information at https://www.ncbi.nlm.nih.gov/.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.
Author details

1. Department of Oral- and Maxillofacial Surgery, University Medical Center Mainz, Augustusplatz 2, 55131 Mainz, Germany.
2. Department of Oral and Maxillofacial Surgery, Federal Armed Forces Hospital, Rubenacher Straße 170, 56072 Koblenz, Germany.

Received: 23 February 2022   Accepted: 7 April 2022
Published online: 16 April 2022

References

1. Isaacs S, Schwetz N, Boyar R, McNicoll A. Bleeding disorders: characterization, dental considerations and management. J Can Dent Assoc. 2006;72(9):827.
2. Peyvandi F, Garagolzi L, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–97.
3. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104(5):1243–52.
4. Heimes D, Kämmerer PW. Grenchenfrage: Blutgerinnungshemmer vor der Operation absetzen oder nicht? der junge Zahnarzt. 2020;6.
5. Rasaratnam L, Chowdary P, Pollard D, Subel B, Harrington C, Darbar UR. Risk-based management of dental procedures in patients with inherited bleeding disorders: development of a Dental Bleeding Risk Assessment and Treatment Tool (DeBRTT). Haemophilia. 2017;23(2):247–54.
6. Blomback M, Johansson G, Johnsson H, Swedenborg J, Wabo E. Surgery in patients with von Willebrand's disease. Br J Surg. 1989;76(4):398–400.
7. Kang M, Kang A. Dental implant therapy on a patient with von Willebrand disease. Br J Surg. 1989;76(4):398–400.
8. Reich W, Krwałsky MS, Wolf HH, Schubert J. Bleeding complications after oral surgery in patients with compromised haemostasis: incidence and management. Oral Maxillofac Surg. 2009;13(2):73–7.
9. Kämmerer PW, Klein MO. Hämosthile und zahnärztliche Behandlung. Zahnarztmit. 2009;59(10):40–6.
10. De Padua V, Romeo U, Santoro C, Bosco R, Baldacci E, Ferretti A, et al. Dental invasive procedures in von Willebrand disease: experience of a single center. Helyont. 2020;6(2):e03426.
11. Lavin M, Aguilà S, Schneppenheim S, Dalton N, Jones KL, O’Sullivan JM, et al. Significant gynaecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018;2(14):1784–91.
12. Lavin M, Aguilà S, Schneppenheim S, Dalton N, Jones KL, O’Sullivan JM, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017;130(21):e10344–53.
13. Doherty D, Lavin M, O’Sullivan JM, Ryan K, O’Connell NM, Dougall A, et al. Management of elective procedures in low von Willebrand factor patients in the LoVIC study. J Thromb Haemost. 2020;19:701.
14. Liras A, Romeo U. Dental management of patients with haemophilia in the era of recombinant treatments: increased efficacy and decreased clinical risk. BMJ Case Rep. 2019;12(4).
15. Kar A. Making haemophilia a global priority. Lancet. 2012;380(9838):216–7.
16. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Weller J, Buttchereit I, Kämmerer PW. "Die Krankheit der Könige”—interdisciplinary Extraktions therapie unter schwerer Hämosthile. Zahnarzt Mit. 2020;110(1):56–9.
17. Weller J, Buttcireit I, Kämmerer PW. „Die Krankheit der König“—inter-diszpli ne Extraktions therapie unter schwerer Hämosthile. Zahnarzt Mit. 2020;110(1):56–9.
18. Fiorillo L, De Stefano R, Cervino G, Crimi S, Bianchi A, Campagna P, et al. Oral and psychological alterations in haemophilic patients. Biomedines. 2019;7(2):33.
19. Anderson JA, Brewer A, Creagh D, Hook S, Mainwaring J, McKernan A, et al. Guidance on the dental management of patients with haemophilia and congenital bleeding disorders. Br Dent J. 2013;215(10):497–501.
20. Calvo-Guirado JL, Romanos GE, Delgado-Ruiz RA. Infected tooth extraction, bone grafting, immediate implant placement and immediate temporary crown insertion in a patient with severe type B hemophilia. BMJ Case Rep. 2019;12(3).
21. Osooli M, Berntorp E. Inhibitors in haemophilia: what have we learned from registries? A systematic review. J Intern Med. 2015;277(1):1–15.
22. Bakjin B, Dougall A. Current state of play regarding dental extractions in patients with haemophilia: consensus or evidence-based practice? A review of the literature. Haemophilia. 2020;26(2):183–99.
23. Zanon E, Brandolin B, Baggioro G, Bacci C. Complex dental extractions in a patient with severe haemophilia A and inhibitors treated with activated prothrombin complex concentrate. Blood Transfus. 2012;10(2):225–7.
24. Laino L, Ciccii M, Fiorillo L, Crimi S, Bianchi A, Amoroso G, et al. Surgical risk on patients with coagulopathies: guidelines on hemophilic patients for oro-maxillofacial surgery. Int J Environ Res Public Health. 2019;16(8):1386.
25. Dougall A, Appleby D, Smith G, Maddern L, Parkinson L, Daly B. Safety of buccal infiltration local anaesthesia for dental procedures. Haemophilia. 2019;25(2):270–5.
26. Hewson I, Makhalilab P, Street A, McCarthy P, Walsh M. Dental surgery with minimal factor support in the inherited bleeding disorder population at the Alfred Hospital. Haemophilia. 2011;17(1):185–8.
27. van Gaalen KP, Engelen ET, Mauser-Bunschoten EP, van Es RJ, Schutgens RE. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev. 2019;4:CD011385.
28. Rodriguez-Merchan EC. What does the ‘Cochrane database of systematic reviews’ tell us about hemophilia? Expert Rev Hematol. 2019;12(11):919–22.
29. Tapper EB, Robson SC, Malik R. Coagulopathy in cirrhosis—the role of the platelet in hemostasis. J Hepatol. 2013;59(4):889–90.
30. Saab S, Brown RS Jr. Management of thrombocytopenia in patients with chronic liver disease. Dig Dis Sci. 2019;64(10):2757–68.
31. Bashour FN, Teran JC, Mullend KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol. 2000;95(10):2936–9.
32. Pereira Tdos S, Pelinissi FC, Ruas BM, Avelar LP, da Fonseca VUJ, de Abreu MH, et al. Postoperative complications after dental extraction in pretransplant patients. Spec Care Dentist. 2016;36(3):277–81.
33. Nizarnal N, Rafique S. Special care dentistry: part 3. Dental management of patients with medical conditions causing acquired bleeding disorders. Dent Update. 2013;40(10):805–8.
34. Efegolu C, Sipahi Calis A, Karasu Z, Koca H, Boyacioglu H. Prospective randomized single-blind study of post-operative bleeding after minor oral surgery in patients with cirrhosis. Turk J Gastroenterol. 2019;30(2):171–6.
35. Poosd F. Review article: thrombocytopenia in cirrhosis liver disease. Aliment Pharmacol Ther. 2007;26(Suppl 1):5–11.
36. Helmersius-Hietala J, Abegg F, Meurman JH, Nordin A, Isoniemi H. Oral surgery in liver transplant candidates: a retrospective study on delayed bleeding and other complications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(5):490–5.
37. Greenwood M, Meechan JG. General medicine and surgery for dental practitioners. Part 5: liver disease. Br Dent J. 2003;195(2):71–3.
38. Moosajee S, Rafique S. Dental management of patients with acquired and congenital bleeding disorders. Prim Dent J. 2020;9(2):47–55.
39. Brigo S, Mancuso E, Pellicano R. Dentistry and oral and maxillofacial surgery in the patient with liver disease: key messages for clinical practice. Minerva Stomatol. 2019;68(4):192–9.
40. Costa FO, Lages EJP, Lages EMB, Cota LOM. Periodontitis in individuals with liver cirrhosis: a case-control study. J Clin Periodontol. 2019;46(10):991–8.
41. Di Profio B, Inoue G, Maruic V, de Francq BN, Romito GA, Ortega KL, et al. Periodontal status of liver transplant candidates and healthy controls. J Periodontol. 2019;80(11):2383–9.
42. Gronkjaer LL, Holmstrup P, Schou S, Kongstad J, Jepsen P, Vilstrup H. Periodontitis in patients with cirrhosis: a cross-sectional study. BMC Oral Health. 2018;18(1):22.
43. Coccero N, Bezzi M, Martini S, Carossa S. Oral surgical treatment of patients with chronic liver disease: assessments of bleeding and its relationship with thrombocytopenia and blood coagulation parameters. J Oral Maxillofac Surg. 2017;75(1):28–34.
44. Cocero N, Frascolinco C, Berta GN, Carossa S. Is it safe to remove teeth in liver transplant patients without antibiotics? A retrospective study of 346 patients. J Oral Maxillofac Surg. 2019;77(8):1557–65.

45. Blumberg N, Heal JM, Phillips GL. Platelet transfusions: trigger, dose, benefits, and risks. F1000 Med Rep. 2010;2:5.

46. Perdigao JP, de Almeida PC, Rocha TD, Mota MR, Soares EC, Alves AP, et al. Postoperative bleeding after dental extraction in liver pretransplant patients. J Oral Maxillofac Surg. 2012;70(3):e177–84.

47. Medina JB, Andrade NS, de Paula EF, Bezinnelli L, Franco JB, Gallottini M, et al. Bleeding during and after dental extractions in patients with liver cirrhosis. Int J Oral Maxillofac Surg. 2018;47(12):1543–9.

48. Stanca CM, Montazem AH, Lawal A, Zhang JX, Schiano TD. Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial. J Oral Maxillofac Surg. 2010;68(1):138–43.

49. Lieberman BL, Kennedy MK, Lorenzo DR, Reed LJ, Adamo AK, Cardo VA Jr, et al. Control of life-threatening head and neck hemorrhage after dental extractions: a case report. J Oral Maxillofac Surg. 2010;68(9):2311–9.

50. Pham N, Sivapatham T, Hussain MS, Bhalla T, Masaryk TJ, Hui FK. Particle embolization of the bilateral superior and inferior alveolar arteries for life-threatening dental socket hemorrhage. J Neurol Intervent Surg. 2012;4(4):e20.

51. Kauhanen K. Lineage-specific hematopoietic growth factors. N Engl J Med. 2006;354(19):2034–45.

52. Yuan Q, Xiong QC, Gupta M, Lopez-Pintor RM, Chen XL, Seriwatanachai D, et al. Dental implant treatment for renal failure patients on dialysis: a clinical guideline. Int J Oral Sci. 2017;9(3):125–32.

53. Nizari N, Rafique S. Special Care Dentistry: Part 2. Dental management of patients with drug-related acquired bleeding disorders. Dent Update. 2013;40(9):711–2.

54. Costantinides F, Castronovo G, Vettori E, Fratini C, Artejo ML, Bevilacqua L, et al. Dental care for patients with end-stage renal disease and undergoing hemodialysis. Int J Dent. 2018;2018:9610892.

55. Georgakopoulos EA, Achtian MD, Afentoulide N. Dental management of patients before and after renal transplantation. stomatologia. 2011;13(4):107–12.

56. Salf A, Adkins A, Kewley V, Woywodt A, Brookes V, Kewley L, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179(9):1469.

57. Agnelli G, Hoffmann U, Hainaut P, Gaine S, Ay C, Coppens M, et al. ETNA-VTE Europe: benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. Thromb Res. 2020;196:297–304.

58. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630–9.

59. Douketis JD, Sproupolous AC, Duncan J, Carlier M, Le Gal G, Tafur AJ, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2015;175(11):1658–63.

60. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.

61. Saviga J, Nagata Y, Yamaguchi T, Iwai T, Yamaguchi J, Hijkata S, et al. Comparison of direct oral anticoagulants and warfarin regarding mid-term adverse events in patients with atrial fibrillation undergoing catheter ablation. J Arrhythm. 2018;34(4):428–34.

62. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.

63. Levy JH, Douketis J, Weitz JL. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018;15(5):273–81.

64. Kim KS, Song JW, Soh S, Kwak YL, Shim JK. Perioperative management of patients receiving non-vitamin K antagonist oral anticoagulants: up-to-date recommendations. Anesth Pain Med (Seoul). 2020;15(2):133–42.

65. Connolly SJ, Milking TJ Jr, Eikelboom JW, Gibson CM, Cummutes JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor xa inhibitors. N Engl J Med. 2016;375(12):1131–41.

66. Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med. 1998;158(15):1610–6.

67. Wahl MJ. Myths of dental surgery in patients receiving anticoagulant therapy. J Am Dent Assoc. 2000;131(1):77–81.

68. Garcia DA, Regan S, Hernandez LE, Uehyday A, Baker J, Othman M, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168(11):1639–60.

69. Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AG, Bates SM, et al. Single-arm study of bridging therapy with low-molecular-weight heparin in patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110(12):1658–63.

70. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164(12):1319–26.

71. Douketis JD, Sproupolous AC, Duncan J, Carlier M, Le Gal G, Tafur AJ, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179:1469.

72. Kämmerer PW, Al-Nawas B. Oral surgery and kidney transplant Part 1. Dent Update. 2011;38(3):179–82.

73. Agnelli G, Hoffmann U, Hainaut P, Gaine S, Ay C, Ottens M, et al. VTNEurope: benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. Thromb Res. 2020;196;297–304.

74. Siegel D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Perioperative heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630–9.

75. Douketis JD, Sproupolous AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823–33.

76. Dunn AS, Sproupolous AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: The Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5(11):2211–8.

77. Shaw JR, Kaplovitch E, Douketis J. Perioperative management of oral anticoagulation. Med Clin North Am. 2020;104(4):799–26.

78. Kuo HC, Liu FL, Chen JT, Cheng YG, Tan KM, Tai IH. Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: a systematic review and meta-analysis. Clin Cardiol. 2020;43(5):441–9.

79. Yong JW, Yang LX, Ohene BE, Zhou YJ, Wang ZJ. Perioperative heparin bridging in patients receiving oral anticoagulation: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2017;17(1):295.

80. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S, et al. Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: a systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630–9.

81. Douketis JD, Sproupolous AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. J Am Soc Nephrol. 2013;24(9):1658–63.

82. Kämmerer PW, Frech B, Liese J, Schiezigt E, Al-Nawas B. Oral surgery during therapy with anticoagulants—a systematic review. Clin Oral Investig. 2015;19(2):171–80.
88. Shi Q, Xu J, Zhang T, Zhang B, Liu H. Post-operative bleeding risk in dental surgery for patients on oral anticoagulant therapy: a meta-analysis of observational studies. Front Pharmacol. 2017;8:538.

89. Chahine J, Khoudary MN, Naar S. Anticoagulation use prior to common dental procedures: a systematic review. Cardiol Res Pract. 2019;2019:9308631.

90. Iwabuchi H, Imai Y, Asanami S, Shirakawa M, Yamane GY, Oguchi H, et al. Evaluation of postextraction bleeding incidence to compare patients receiving and not receiving warfarin therapy: a cross-sectional, multicentre, observational study. BMJ Open. 2014;4(12):e005777.

91. Yang S, Shi Q, Liu J, Li J, Xu J. Should oral anticoagulant therapy be continued during dental extraction? A meta-analysis. BMC Oral Health. 2016;16(1):81.

92. Hanken H, Gröbe A, Heiland M, Smeets R, Klüewe L, Wikner J, et al. Postoperative bleeding risk for oral surgery under continued rivaroxaban anticoagulant therapy. Clin Oral Invest. 2016;20(6):1279–82.

93. Galletti G, Alfonsi F, Raffaele A, Valente NA, Chatelain S, Kolerman R, et al. Implant placement in patients under treatment with rivaroxaban: a retrospective clinical study. Int J Environ Res Public Health. 2020;17(12):4607.

94. Manor Y, Peleg O, Mjiritsky E, Manor A, Reiter S. A retrospective analysis of dental implantation under anticoagulant treatment. Clin Oral Investig. 2020.

95. Mauruprize C, Khonsari RH, Razouk O, Goudot P, Lesclous P, Descroix V, et al. Evaluation of postextraction bleeding incidence to compare patients receiving and not receiving warfarin therapy: a meta-analysis of observational studies. Front Pharmacol. 2017;8:58.

96. Verma A, Ha ACT, Rutka JT, Verma S. What surgeons should know about non-vitamin K oral anticoagulants: a review. JAMA Surg. 2018;153(6):577–85.

97. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Derex L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;20(8):1231–42.

98. Hamada T, Yamasu H, Nakai K, Isayama H, Matsui H, Horiguchi H, et al. Bleeding after endoscopic sphincterotomy or papillary balloon dilation among users of antithrombotic agents. Endoscopy. 2015;47(11):997–1004.

99. Hanken H, Tieck F, Klüewe L, Smeets R, Heiland M, Precht C, et al. Lack of evidence for increased postoperative bleeding risk for dental osteotomy with continued aspirin therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;19(2):209–16.

100. Malik AH, Majeed S. Effect of antiplatelet therapy on minor dental procedures. Natl J Maxillofac Surg. 2020;11(1):64–6.

101. Burger W, Chemnitz JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. J Intern Med. 2005;257(5):399–414.

102. Bondi-Zoccai GG, Lotriente M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667–74.

103. Little JW, Miller CS, Henry RG, McIntosh BA. Antithrombotic agents: implications in dentistry. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93(5):544–51.

104. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, et al. The perioperative management of antithrombotic therapy—American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):2995–3395.

105. Mahmood H, Siddique I, McKechnie A. Antiplatelet drugs: a review of pharmacology and the perioperative management of patients in oral and maxillofacial surgery. Ann R Coll Surg Engl. 2020;102(1):9–13.

106. Airoldi F, Colombo A, Monici N, Latib A, Cosgrace J, Buelllesfeld L, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine therapy. Circulation. 2007;116(7):745–54.

107. Vivioti SD, Braunwald E, Angiolillo DJ, Messel S, Dalby AJ, Verheugt FW, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626–36.

108. Krishnan B, Prasad GA, Madhan B, Saravanan R, Mote NP, Aklesh R. Post-extraction bleeding complications in patients on uninterrupted dual antiplatelet therapy—a prospective study. Clin Oral Investig. 2020.

109. Bajkin BV, Selakovic SD, Mirkovic SM, Sarcev IN, Tadic AJ, Milekic BR. Comparison of efficacy of local hemostatic modalities in anticoagulated patients undergoing tooth extractions. Vox Sang. 2014;71(12):1097–101.

110. Soares EC, Costa FW, Bezerra TP, Nogueira CB, de Barros Silva PG, Batista SH, et al. Postoperative hemostatic efficacy of gauze soaked in tranexamic acid, fibrin sponge, and dry gauze compression following dental extractions in anticoagulated patients with cardiovascular disease: a prospective, randomized study. Oral Maxillofac Surg. 2015;19(2):209–16.

111. Yamada SI, Hasегawa T, Soutome S, Yoshimura H, Miyakoshi M, Ueda N, et al. Prevalence of and risk factors for postoperative hemorrhage after lower third molar extraction on warfarin therapy: a multicenter retrospective study in Japan. Odontology. 2020;108(3):462–9.

112. Hamzah NA, Graf HL, Kalderovic MR, Meyer AL, Dieterlen MT, Hemp-Rich A. Haemostasis in oral surgical procedures involving patients with a ventricular assist device. Int J Oral Maxillofac Surg. 2020;49(10):1355–9.

113. Kumar KR, Kumar J, Sarvagna J, Gaddie P, Chikkaboorah S. Hemostasis and post-operative care of oral surgical wounds by Hemcon dental dressing in patients on oral anticoagulant therapy: a split mouth randomized controlled clinical trial. J Clin Diag Res. 2016;10(9):ZC37–40.

114. Felix J, Chaban P, Ouanounou A. Dental management of patients undergoing antithrombotic therapy. J Can Dent Assoc. 2020;86:k17.

115. Lombardi N, Varoni EM, Sorrentino D, Lodi G. International normalized ratio (INR) values in patients receiving oral vitamin K antagonists and undergoing oral surgery: a clinical audit. Spec Care Dentist. 2020;40(4):374–81.

116. Engelen ET, Schutgens RE, Mauser-Bunschoten EP, van Es RJ, van Galen KP. Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev. 2018;7:CD012293.